Efficacy of Hypotonic 0.18% Sodium Hyaluronate Eye Drops in Patients With Dry Eye Disease

Lee, Hyo Seok; Ji, Yong Sok; Yoon, Kyung Chul

doi:10.1097/ico.0000000000000165

Cited by 29 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings obtained here reveal that the VLC meibum lipids are crucial for the prevention of dry eye disease. To date, only therapeutic agents targeted to the glycocalyx and aqueous layers have been developed (32)(33)(34). However, with the consideration that meibomian gland dysfunction is the most common cause of evaporative dry eye (7,8), therapeutic agents targeting the TFLL would be a more effective treatment for the disease.…”

Section: Discussionmentioning

confidence: 99%

Very long‐chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice

Sassa

Tadaki

Kanazawa³

et al. 2018

FASEB j.

View full text Add to dashboard Cite

Lipids secreted from the meibomian gland (meibum) form the superficial layer of the tear film and prevent water evaporation from the ocular surface and infection. Here, we identified the fatty acid (FA) elongases responsible for the synthesis of very long-chain FAs (VLCFAs) that constitute the meibum lipids. Elongation of VLCFAs (ELOVL)1 is primarily responsible for the production of saturated VLCFAs, whereas ELOVL1, ELOVL3, and ELOVL4 redundantly participate in the synthesis of monounsaturated VLCFAs. Gene disruption of Elovl1 in mice shortened acyl moieties in the 2 major meibum lipids: cholesteryl esters and wax esters. These changes were associated with dry eye phenotypes, including increases in eye-blink frequency and water evaporation from the ocular surface at younger ages. Aged Elovl1 mutant mice developed corneal opacity with vascular invasion, accompanied by epidermalization of the cornea. Thus, in addition to the well-known VLC ceramides (acylceramides) in the epidermis, VLC meibum lipids are barrier-forming lipids.-Sassa, T., Tadaki, M., Kiyonari, H., Kihara, A. Very long-chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Very long‐chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice

Sassa

Tadaki

Kanazawa³

et al. 2018

FASEB j.

View full text Add to dashboard Cite

show abstract

“… 13–15 HA artificial tear eye drops were also shown to improve ocular surface irregularity, stabilize precorneal tear film, and ameliorate the intensity of dry eye symptoms. 16 , 17 Although traditional formulations contain HA at 0.1% concentration, other HA formulations with higher concentrations have recently been introduced.…”

Section: Introductionmentioning

confidence: 99%

Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye

You

Jin

et al. 2018

Journal of Ocular Pharmacology and Therapeutics

Self Cite

View full text Add to dashboard Cite

Purpose: To compare the efficacy of 0.1%, 0.18%, and 0.3% hyaluronic acid (HA) artificial tear in the treatment of experimental dry eye (EDE).Methods: EDE was established in female C57BL/6 mice through an air draft and subcutaneous scopolamine injection. The mice were divided into 5 groups according to topical treatment regimens (n = 5 each): EDE control, balanced salt solution (BSS), preservative-free 0.1% HA, 0.18% HA, and 0.3% HA. The tear film break-up time (TBUT) and corneal fluorescein staining scores were measured 5, 10, 14, 21, and 28 days after treatment. The corneal smoothness scores were measured. In addition, periodic acid–Schiff (PAS) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were performed.Results: The values for TBUT and corneal fluorescein staining showed greater improvements in all the HA groups (P < 0.05) than in the EDE and BSS groups after 10 days of treatment. Mice treated with 0.3% HA showed a more significant improvement in all clinical parameters than did those in the EDE control, BSS, 0.1% HA, and 0.18% HA groups (all P < 0.05) after 28 days of treatment. The goblet cell counts were higher in the 0.3% and 0.18% HA groups than in the 0.1% HA group. The number of TUNEL-positive cells was the lowest in the 0.3% HA group.Conclusions: In EDE, 0.3% HA artificial tears are more effective than the 0.1% and 0.18% HA in improving tear film instability and ocular surface staining and irregularity, in increasing the number of conjunctival goblet cells, and in decreasing corneal epithelial apoptosis.

show abstract

“…[7][8][9] Hyaluronic acid is widely used as a topical ocular tear replacement therapy and is the standard of care for dry eye in Europe and Asia. 10 These HA-containing solutions provide transient, symptomatic relief and have excellent safety profiles. The main limitation with many of these solutions is the rapid clearance of the HA from the eye, requiring that drops be administered at least four times a day and often more frequently.…”

mentioning

confidence: 99%

Topical Cross-Linked HA-Based Hydrogel Accelerates Closure of Corneal Epithelial Defects and Repair of Stromal Ulceration in Companion Animals

Williams

Wirostko²,

Gum

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

Efficacy of Hypotonic 0.18% Sodium Hyaluronate Eye Drops in Patients With Dry Eye Disease

Abstract: Hypotonic 0.18% SH eye drops seemed to be effective in improving tear film stability and ocular surface integrity compared with isotonic 0.1% SH eye drops in patients with mild DED.

Cited by 29 publications

References 35 publications

Very long‐chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice

Very long‐chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice

Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye

Topical Cross-Linked HA-Based Hydrogel Accelerates Closure of Corneal Epithelial Defects and Repair of Stromal Ulceration in Companion Animals

Contact Info

Product

Resources

About